['gastric cancer', 'gastroesophageal junction adenocarcinoma', 'non-small cell lung cancer', 'hepatocellular carcinoma']
['ramucirumab', 'medi4736']

        Inclusion Criteria:

          -  Measurable metastatic disease or locally advanced and unresectable disease

               -  Has histopathologically confirmed gastric or GEJ adenocarcinoma with documented
                  disease progression after 1-2 prior lines of systemic therapy

               -  Has histopathologically confirmed nonsquamous or squamous NSCLC with documented
                  disease progression after 1-3 prior lines of systemic therapy

               -  Has histopathologically or cytologically confirmed HCC, Child-Pugh Class A, with
                  documented disease progression during or after discontinuation of sorafenib
                  therapy, or intolerance of sorafenib therapy, and an α-fetoprotein (AFP) ≥ 1.5x
                  upper limit of normal

          -  Availability of tumor tissue for biomarker analysis

          -  Has an Eastern Cooperative Oncology Group Performance Status of 0 or 1

          -  Has adequate organ function

        Exclusion Criteria:

          -  Has known brain metastases

          -  Has a history of prior cancers not included in this study that were either not treated
             with curative intent or have been active within the past 5 years

          -  History of allogeneic organ transplant

          -  Has active or prior documented autoimmune disease within the past 24 months

          -  Has human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome
             (AIDS)-related illness, or a history of immunodeficiency

          -  Has active hepatitis B or hepatitis C infection, or co-infection with both hepatitis B
             and C virus

          -  For gastric/GEJ and NSCLC participants, has chronic hepatitis B or hepatitis C
             infection. (For HCC participants, those with chronic hepatitis B virus [HBV] infection
             with a negative HBV deoxyribonucleic acid [DNA] test and who are on antiviral therapy,
             and those with chronic hepatitis C virus [HCV] infection are eligible)

          -  Has a history of interstitial lung disease, idiopathic pulmonary fibrosis,
             pneumoconiosis, non-infections pneumonitis, radiation-induced or drug-induced
             pneumonitis

          -  Has received any previous systemic therapy targeting programmed death (PD) 1 or
             PD-ligand 1/2 signaling pathways, and other immune checkpoint inhibitors

          -  Have received previous systemic therapy with ramucirumab
      